EP2107054A1 — Antiproliferative compounds and therapeutic uses thereof
Assigned to Universite de Geneve · Expires 2009-10-07 · 17y expired
What this patent protects
Inhibitors of the oncogenic tyrosine kinase ALK and of the Bcr-Abl mutant T315I Bcr-Abl, such as a compound of formula (I): wherein Q, T, W, K, J, Y, X, Z are independently selected from C, N, S, O, provided that the corresponding rings are (hetero)aromatic; n = 0 or 1; q…
USPTO Abstract
Inhibitors of the oncogenic tyrosine kinase ALK and of the Bcr-Abl mutant T315I Bcr-Abl, such as a compound of formula (I): wherein Q, T, W, K, J, Y, X, Z are independently selected from C, N, S, O, provided that the corresponding rings are (hetero)aromatic; n = 0 or 1; q = 1 or 2; pharmaceutical compositions containing the same and their use for the treatment of hyper-proliferative diseases.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.